Related content

Pharmacodynamic study of 131I-labeled CA215 antibody on an animal model of estrogen-resistant OC-3-VGH ovarian cancer

By            

Experimental and Therapeutic Medicine, Vol. 10, Iss. 2, 2015-01 ,pp. : 572-578

Spandidos Publications

Access to resources Recommend Favorite

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

By Russell P.   Ow K.   Tam P.   Juarez J.   Kingsley E.   Qu C.   Li Y.   Cozzi P.   Martiniello-Wilks R.  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 11, 2004-11 ,pp. : 995-1004

Springer Publishing Company

Access to resources Recommend Favorite

PET in Anti-Cancer Drug Development and Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 2, Iss. 3, 2007-11 ,pp. : 259-263

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study

By Sebastian Martin   Passlick Bernward   Friccius-Quecke Hilke   Jäger Michael   Lindhofer Horst   Kanniess Frank   Wiewrodt Rainer   Thiel Eckhard   Buhl Roland   Schmittel Alexander  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 10, 2007-10 ,pp. : 1637-1644

Springer Publishing Company

Access to resources Recommend Favorite

Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer

By Mitsiades Constantine   Lembessis Peter   Sourla Antigone   Milathianakis Constantine  

Clinical and Experimental Metastasis, Vol. 21, Iss. 6, 2004-10 ,pp. : 495-505

Springer Publishing Company

Access to resources Recommend Favorite